Souhaitez-vous accéder aux communiqués récents ?

OCTOPUS AIM VCT PLC Admission of Further Securities to Trading Further to the Company's Issue of Equity and Total Voting Rights announcement on 1 April 2026 in respect of the allotment of new...

OCTOPUS AIM VCT PLC Admission of Further Securities to Trading Further to the Company's Issue of Equity and Total Voting Rights announcement on 26 March 2026 in respect of the allotment of new...

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- The global asset and wealth management (AWM) and alternatives industries are entering a new phase in which firms need to translate years of investment in...

LONDON and PHILADELPHIA, April 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a...

Company Announcement Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) ...

The facility is for £320 million upsized from £240 million, and now extends for a two-year term, providing long-term funding to support the continued grow.

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NB...